ASH 2023 | Unmet needs in hemophilia treatment
Glaivy Batsuli, MD, Stanford University, Stanford, CA, discusses challenges that remain in treating patients with hemophilia. She mentions the unmet need for patients with hemophilia B without inhibitors and the importance of improving the quality of life for these patients. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
One of the big unmet needs still remains hemophilia B without inhibitors, and the two products that are kind of being reviewed or going to be reviewed by the FDA hopefully will address that because that’s a patient population that still doesn’t have a currently approved therapy besides the bypassing agents, particularly recombinant VIIa. So I think that’s an area that’s still untapped in terms of hemophilia treatment...
One of the big unmet needs still remains hemophilia B without inhibitors, and the two products that are kind of being reviewed or going to be reviewed by the FDA hopefully will address that because that’s a patient population that still doesn’t have a currently approved therapy besides the bypassing agents, particularly recombinant VIIa. So I think that’s an area that’s still untapped in terms of hemophilia treatment. And I think as we’re able to have access to new drugs and and just think about hemophilia differently, just still kind of approaching hemophilia in terms of how do we optimize quality of life and how do we allow for individuals to be able to kind of do regular activities and not have to worry about bleeding? And so kind of continuing to push the needle forward to improve their quality of life, both for men with hemophilia, but also women with hemophilia. I think there’s been a lot of research and really a lot of advocacy in terms of women also being able to access some of these therapies and receive treatment for their bleeding symptoms as well.
Read more...
